Phase III CheckMate-577 trial of Opdivo shows benefits in oesophageal cancer.- BMS

Bristol Myers Squibb announced that checkpoint inhibitor treatment Opdivo (nivolumab) demonstrated its efficacy in the phase III CheckMate-577 trial involving patients with oesophageal or gastroesophageal junction cancers who had previously received neoadjuvant chemoradiation therapy and tumour resection. The results showed that median disease-free survival doubled in patients receiving Opdivo treatment versus those patients receiving placebo after surgery. The median duration of treatment for patients in the Opdivo arm was 10.1 months compared to 9 months in the placebo arm. The treatment was also well tolerated, with an acceptable safety profile versus placebo. BMS intendeds to discuss the results from the CheckMate-577 study with health authorities. Data were presented at the 2020 European Society for Medical Oncology virtual congress.